Open Orphan #ORPH – Successful extension of contract with top-3 global pharmaceutical client underpins 2021 revenue growth expectations December 22, 2020 – Posted in: Open Orphan (ORPH), Uncategorized

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces a contract renewal extending its consultancy services with a major top-3 global pharmaceutical client to December 2021. Through the Venn Life Sciences team in the Breda office in the Netherlands, Open Orphan provides independent, up-to-date and hands-on Chemistry, Manufacturing & Control (“CMC”) consultancy services to a leading global…

Pharma Tech Article – Open Orphan #ORPH – Accelerated Vaccine Development with Human Challenge Studies December 7, 2020 – Posted in: Open Orphan (ORPH)

Pharma Tech Article – Open Orphan #ORPH – Accelerated Vaccine Development with Human Challenge Studies Pharmaceutical companies worldwide are joining global efforts to combat, diagnose, treat and prevent infections from COVID-19. As we have seen, the search for vaccines and possible treatment to curb the transmission and reduce the mortality and morbidity produced by the virus is in overdrive. Link here to read the full article…

Open Orphan #ORPH subsidiary Venn Life Sciences wins two new contracts – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce its subsidiary Venn Life Sciences (“Venn”) has been awarded two new contracts. The first contract, which will commence immediately, is a COVID-19 study for a European pharmaceutical company which involves 200 patients in 50 sites across 5 countries around the world. Venn’s…

Open Orphan #ORPH Announces New £2.5m Influenza Challenge Study Contract Win November 5, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce the signing of a £2.5 million contract by hVIVO, a subsidiary of Open Orphan, to conduct an Influenza human challenge study with a US biotechnology company. The study is expected to commence at hVIVO’s 24-bedroom quarantine clinic in East London in H2…

Daily Mail Stock Watch – Open Orphan #ORPH – October 30th 2020 October 31, 2020 – Posted in: Open Orphan (ORPH)

Daily Mail Stock Watch – Open Orphan #ORPH – October 30th 2020

Open Orphan #ORPH – New 2-year contract with a tier 1 German pharmaceutical company October 30, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new 2-year contract with a tier 1 German pharmaceutical company which is one of Europe’s top research-driven pharmaceutical companies. The contract guarantees annual revenue, for the next two years, with work under the contract to commence this month. The contract will see…

Open Orphan #ORPH – Interim Results for 6 months ended 30 June, will be operationally profitable in Q4 September 30, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan Plc, a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical studies is pleased to announce its interim results for the six months ended 30 June 2020. The interim results include the first six months of hVIVO group (“hVIVO”) following its acquisition by Open Orphan Plc on the 17 January 2020. Operational Highlights: · Completed the acquisition of hVIVO…

Open Orphan #ORPH – New £4.3m Challenge Study Contract Win with Global Top 10 Vaccine Company September 28, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new £4.3 million contract to conduct a human viral challenge study utilising one of our 8 traditional challenge study models for another of the global top 10 vaccine companies. This trial will be conducted in the Company’s dedicated human viral challenge…

Open Orphan #ORPH – Venn Life Sciences New Contract Win September 22, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce Open Orphan’s Paris subsidiary Venn Life Sciences (“Venn”) has secured an important new contract to support a major European pharmaceutical company. The Paris team of Venn will be assisting a prospective, multicentre, longitudinal, non-interventional oncology study which is expected to enrol over…

Open Orphan #ORPH – New Contract Win with Carna Bioscience August 4, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce the signing of a new contract with Carna Bioscience ( www.carnabio.com ) for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for Venn Life Sciences (“Venn”) over the next twelve months. The contract sees the…